US 12,419,957 B2
Delivery and formulation of engineered nucleic acids
Antonin De Fougerolles, Waterloo (BE); and Sayda M. Elbashir, Cambridge, MA (US)
Assigned to ModernaTX, Inc., Cambridge, MA (US)
Filed by ModernaTX, Inc., Cambridge, MA (US)
Filed on Aug. 30, 2024, as Appl. No. 18/821,068.
Application 15/379,284 is a division of application No. 14/337,513, filed on Jul. 22, 2014, granted, now 9,533,047, issued on Jan. 3, 2017.
Application 18/821,068 is a continuation of application No. 18/417,715, filed on Jan. 19, 2024.
Application 18/417,715 is a continuation of application No. 17/141,753, filed on Jan. 5, 2021, granted, now 11,911,474, issued on Feb. 27, 2024.
Application 17/141,753 is a continuation of application No. 15/927,730, filed on Mar. 21, 2018, granted, now 10,898,574, issued on Jan. 26, 2021.
Application 15/927,730 is a continuation of application No. 15/379,284, filed on Dec. 14, 2016, granted, now 9,950,068, issued on Apr. 24, 2018.
Application 14/337,513 is a continuation of application No. 13/897,362, filed on May 18, 2013, abandoned.
Application 13/897,362 is a continuation of application No. 13/437,034, filed on Apr. 2, 2012, granted, now 8,710,200, issued on Apr. 29, 2014.
Claims priority of provisional application 61/470,451, filed on Mar. 31, 2011.
Prior Publication US 2025/0064937 A1, Feb. 27, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 47/18 (2017.01); A61K 31/7088 (2006.01); A61K 31/7115 (2006.01); A61K 38/19 (2006.01); A61K 38/48 (2006.01); A61K 47/22 (2006.01); A61K 47/28 (2006.01); A61K 48/00 (2006.01); C07K 14/535 (2006.01); C12N 9/64 (2006.01); C12N 15/67 (2006.01); C12N 15/87 (2006.01)
CPC A61K 47/18 (2013.01) [A61K 31/7088 (2013.01); A61K 31/7115 (2013.01); A61K 38/193 (2013.01); A61K 38/4846 (2013.01); A61K 47/22 (2013.01); A61K 47/28 (2013.01); C07K 14/535 (2013.01); C12N 9/644 (2013.01); C12N 15/67 (2013.01); C12N 15/87 (2013.01); A61K 48/00 (2013.01); C12N 2310/335 (2013.01)] 10 Claims
 
1. A messenger RNA (mRNA) comprising an open reading frame encoding a polypeptide, wherein the open reading frame comprises nucleosides consisting of N1-methyl-pseudouridine, adenosine, guanosine, and cytidine.
 
2. The mRNA of claim 1, wherein the mRNA comprises, in the 5′ to 3′ direction,
(a) a 5′ cap structure
(b) a 5′-UTR;
(c) the open reading frame encoding the polypeptide;
(d) a 3′-UTR; and
(e) a polyA tail.